ASGCT Guide Modification Poster

Mar

27

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Mar

9

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Feb

23

Editas Medicine to Participate in Upcoming Investor Conferences